ExCEEd Orphan initiates cooperation with Novartis Hungary for Zolgensma®

The ExCEEd Orphan announces initiation of its consulting cooperation with Novar-tis Hungary for market access, including pricing and reimbursement for Zol-gensma®, the only approved gene therapy for spinal muscular atrophy (SMA).

Get in touch

With real experts in CEE region.

Send us an e-mail